VRT106

Phase 2Small molecule

GGuangzhou Virotech Pharmaceutical Co., Ltd.

VRT106 is one of 121 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerNot yet recruiting

GlioblastomaRecruiting

Solid TumorRecruiting

Gastric CancerPhase 2

Not yet recruiting

GlioblastomaPhase 2

Recruiting

Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

VRT106

GGuangzhou Virotech Pharmaceutical Co., Ltd.

Phase 2

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 4

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Carboplatin AUC-5

Merck & Co.

Preclinical

1 8

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 9

Interleukin 2

EEssen Biotech

Preclinical

2 10

IL-2

FFate Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Study completion

NCT06368921

Q1 2029

Phase 1Recruiting

Solid Tumor

NCT06826313

Q2 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT07486310

PreclinicalRecruiting

HCC

NCT07589244

PreclinicalRecruiting

Glioblastoma

NCT07093814

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT07486310·30 enrolled

HCC1 trial

A Multicenter, Open-label Phase II/III Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Preclinical·NCT07589244·66 enrolled

Glioblastoma1 trial

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Preclinical·NCT07093814·42 enrolled

Solid Tumor1 trial

An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·NCT06826313·12 enrolled

Unspecified1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·NCT06368921·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for VRT106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VRT106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VRT106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Virotech Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangzhou Virotech Pharmaceutical Co., Ltd.

VRT106

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Q2 2029

Trials by Indication[1]

Gastric Cancer1 trial

HCC1 trial

Glioblastoma1 trial

Solid Tumor1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News